<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02574195</url>
  </required_header>
  <id_info>
    <org_study_id>ESR1410209</org_study_id>
    <nct_id>NCT02574195</nct_id>
  </id_info>
  <brief_title>Evolution of Effectiveness of Diabetes Medical Care in Russia</brief_title>
  <official_title>Evolution of Effectiveness of Diabetes Medical Care in Russia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Endocrinology Research Centre, Moscow</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Endocrinology Research Centre, Moscow</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main aim of the present study is to evaluate the prevalence of individual microvascular&#xD;
      and macrovascular complications among diabetes mellitus patients and to determine the&#xD;
      percentage of diabetes mellitus patients achieved HbA1c&lt;7,0%.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Rationale for this Study Primary Existing routine health statistics underestimates the rate&#xD;
      of morbidity due to diabetes complications. To provide more realistic estimation of&#xD;
      morbidity, repeated epidemiological studies are essential in assessment of tendencies in&#xD;
      diabetes medical care at the country level. They allow to reveal issues, which, being&#xD;
      resolved, can contribute to the improvement of diabetes medical care effectiveness.&#xD;
      Guidelines developed with this study data may save healthcare budgets and prevent financial&#xD;
      losses due to diabetes-related morbidity and disability.&#xD;
&#xD;
      Objectives of the Study • Primary objective: To determine the prevalence of individual&#xD;
      microvascular and macrovascular complications among patients with diabetes mellitus type 1&#xD;
      and type 2&#xD;
&#xD;
      • Secondary objective: To determine the percentage of patients with diabetes mellitus type 1&#xD;
      and type 2 achieved HbA1c &lt;7,0%.&#xD;
&#xD;
      Study design The hired medical team (9 specialists) is going to perform the technical&#xD;
      study-related tasks in Moscow Region.&#xD;
&#xD;
      Target population includes approximately 147,000 diabetes mellitus patients included in&#xD;
      Regional Diabetes Mellitus Register, from which patients will be selected via random sampling&#xD;
      (600 patients).&#xD;
&#xD;
      A special rented medical bus will accommodate the study personnel at the place and all the&#xD;
      local study-related activities.&#xD;
&#xD;
      After obtaining a written Informed Consent Form by local endocrinologist the each study&#xD;
      subject will have one study visit, when he or she should appear fasting and the following&#xD;
      data will be collected, tests and examination performed:&#xD;
&#xD;
        -  date of the diagnosis of type 1 or type 2 diabetes mellitus;&#xD;
&#xD;
        -  medical history including coronary heart disease, myocardial infarction, coronary&#xD;
           revascularization, cerebrovascular disease (ischaemic stroke, a transient ischemic&#xD;
           attack), peripheral artery disease, diabetic retinopathy (type, stage, year of&#xD;
           diagnosis), diabetic neuropathy, chronic kidney disease, diabetic foot;&#xD;
&#xD;
        -  blood tests for HbA1c, serum total cholesterol, triglycerides, HDL- cholesterol, serum&#xD;
           creatinine and estimation estimated Glomerular filtration rate by standard CKD-EPI,&#xD;
           alanine-aminotransferase, aspartate-aminotransferase;&#xD;
&#xD;
        -  urine analysis for albumin in spot urine;&#xD;
&#xD;
        -  measurement of height, weight/BMI;&#xD;
&#xD;
        -  measurement of sitting blood pressure, Electocardiogramm;&#xD;
&#xD;
        -  eye examination, including fundoscopy;&#xD;
&#xD;
        -  foot examination, including tests for touch, pain, temperature, and vibration sensation&#xD;
           of the toes and mini-doppler ultrasound vessel study;&#xD;
&#xD;
        -  current pharmacological therapy regimen (medications, daily doses). The medical team&#xD;
           will admit up to 35 study subjects per day. This study has descriptive character. There&#xD;
           is no any comparison to be performed.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2015</start_date>
  <completion_date type="Actual">October 2015</completion_date>
  <primary_completion_date type="Actual">October 2015</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of patients with diabetes mellitus type 1 and type 2diabetes mellitus complications</measure>
    <time_frame>30 days</time_frame>
    <description>macrovascular complications, i.e. with history of&#xD;
chronic heart disease&#xD;
myocardial infarction&#xD;
ischaemic stroke&#xD;
transient ischemic attack&#xD;
any revascularization procedure&#xD;
any peripheral atherosclerosis&#xD;
e) microvascular complications, i.e.&#xD;
diabetic retinopathy&#xD;
diabetic neuropathy&#xD;
albuminuria&#xD;
chronic kidney disease stage f) other complications diagnosed after diabetes mellitus has been established, i.e.&#xD;
foot examination findings</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The percentage of patients with diabetes mellitus type 1 and type 2 achieved HbA1c &lt;7%</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Structure of antidiabetic therapy (% insulin, % OAD mono, % OAD dual, % OAD triple)</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">599</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <condition>Diabetes Mellitus, Type 1</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with type 1 or type 2 Diabetes Mellitus&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
        The subject population for this study must meet the following criteria:&#xD;
&#xD;
          1. Provision of singed subject informed consent&#xD;
&#xD;
          2. Type 1 and type 2 diabetes mellitus Target population includes approximately 147,000&#xD;
             diabetes mellitus patients included in Regional DM Register, from which patients will&#xD;
             be selected via random sampling (600 patients).&#xD;
&#xD;
        The prescription of the medicinal product is clearly separated from the decision to include&#xD;
        the subject in the study.&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
        1. Diagnosis of gestational diabetes mellitus alone.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marina Shestakova</last_name>
    <role>Principal Investigator</role>
    <affiliation>ERC Moscow</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Endocrinology Scientific Center</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>April 2016</verification_date>
  <study_first_submitted>December 18, 2014</study_first_submitted>
  <study_first_submitted_qc>October 9, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 12, 2015</study_first_posted>
  <last_update_submitted>April 5, 2016</last_update_submitted>
  <last_update_submitted_qc>April 5, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 6, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Diabetes Mellitus</keyword>
  <keyword>microvascular complications</keyword>
  <keyword>macrovascular complications</keyword>
  <keyword>epidemiology</keyword>
  <keyword>Russia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

